Sandra M Gurrola
CIK 1618457 · Sr. VP of Finance · last filed 2025-07-07
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$153.8K
Companies
3
Total Filings
46
Lifetime Open-Market Net
$0
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ERNA | Sr. VP of Finance | 110 | $6.15 | $676 | $0 | 5 | 2025-07-07 |
| BTX | Vice President of Finance | 16,953 | $9.03 | $153.1K | $0 | 4 | 2022-06-23 |
| Ernexa Therapeutics Inc. (NTN) Delisted | Former SVP of Finance | 21,617 | $2.70 | $58.4K | $0 | 35 | 2021-03-26 |
Recent Filings · Page 5 of 5
46 filingsForm 4 transactions across all companies, newest first.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2018-10-24 | Ernexa Therapeutics Inc. (NTN) Delisted | Tax (F) | −28 | -$121 | EDGAR |
| 2018-09-25 | Ernexa Therapeutics Inc. (NTN) Delisted | Tax (F) | −169 | -$715 | EDGAR |
| 2018-03-21 | Ernexa Therapeutics Inc. (NTN) Delisted | Grant (A) | +3,000 | $0 | EDGAR |
| 2016-05-26 | Ernexa Therapeutics Inc. (NTN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2015-03-25 | — | Grant (A) | — | $0 | |
| 2014-09-08 | — | Grant (A) | — | $0 |
Showing 41–46 of 46
Prev
Page 5 of 5
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.